These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 25465298)
1. Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. Lee CH; Motzer RJ Urol Oncol; 2015 Jun; 33(6):275-9. PubMed ID: 25465298 [TBL] [Abstract][Full Text] [Related]
2. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Motzer RJ; Escudier B; Gannon A; Figlin RA Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib malate for the treatment of renal cell carcinoma. Wood L Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009 [TBL] [Abstract][Full Text] [Related]
8. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562 [TBL] [Abstract][Full Text] [Related]
10. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. Hutson TE Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373 [TBL] [Abstract][Full Text] [Related]
11. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905 [TBL] [Abstract][Full Text] [Related]
12. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Biswas S; Kelly J; Eisen T Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692 [TBL] [Abstract][Full Text] [Related]
13. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Stein MN; Flaherty KT Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705 [No Abstract] [Full Text] [Related]
14. Sunitinib for the management of advanced renal cell carcinoma. Escudier B Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511 [TBL] [Abstract][Full Text] [Related]
15. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817 [TBL] [Abstract][Full Text] [Related]
16. The use of sunitinib in renal cell carcinoma: where are we now? Czarnecka AM; Szczylik C; Rini B Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545 [TBL] [Abstract][Full Text] [Related]
17. Sunitinib for the treatment of metastatic renal cell carcinoma. Oudard S; Beuselinck B; Decoene J; Albers P Cancer Treat Rev; 2011 May; 37(3):178-84. PubMed ID: 20817406 [TBL] [Abstract][Full Text] [Related]